These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. United States Food and Drug Administration requirements for approval of generic drug products. Meyer MC J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846 [TBL] [Abstract][Full Text] [Related]
6. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300 [TBL] [Abstract][Full Text] [Related]
7. The effectiveness of generic agents in psychopharmacologic treatment. Kumet R; Gelenberg AJ Essent Psychopharmacol; 2005; 6(2):104-11. PubMed ID: 15765794 [TBL] [Abstract][Full Text] [Related]
8. Generic substitution: issues for problematic drugs. Henderson JD; Esham RH South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the bioavailability and bioequivalence of generic medications. Howland RH J Psychosoc Nurs Ment Health Serv; 2010 Jan; 48(1):13-6. PubMed ID: 20102127 [TBL] [Abstract][Full Text] [Related]
13. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs. Quiroz J; Ting N; Wei GC; Burdick RK Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892 [TBL] [Abstract][Full Text] [Related]
14. The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping. Itil TM; Itil KZ J Clin Psychiatry; 1986 Sep; 47 Suppl():20-7. PubMed ID: 3528132 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. Cutler NR J Clin Psychiatry; 2001; 62 Suppl 5():10-3; discussion 23-4. PubMed ID: 11305842 [TBL] [Abstract][Full Text] [Related]
16. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102 [TBL] [Abstract][Full Text] [Related]
18. An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. Knoben JE; Scott GR; Tonelli RJ Am J Hosp Pharm; 1990 Dec; 47(12):2696-700. PubMed ID: 2278285 [TBL] [Abstract][Full Text] [Related]
19. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers. Bongiorno RA; Nutescu EA Semin Thromb Hemost; 2004 Dec; 30(6):619-26. PubMed ID: 15630667 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the bioequivalence of generic versus branded clozapine. Ereshefsky L; Glazer WM J Clin Psychiatry; 2001; 62 Suppl 5():25-7. PubMed ID: 11305845 [No Abstract] [Full Text] [Related] [Next] [New Search]